| Literature DB >> 24196189 |
Andrew J M Cooper1, Soren Brage, Ulf Ekelund, Nicholas J Wareham, Simon J Griffin, Rebecca K Simmons.
Abstract
AIMS/HYPOTHESIS: The aim of our study was to examine the associations between sedentary time (SED-time), time spent in moderate-to-vigorous-intensity physical activity (MVPA), total physical activity energy expenditure (PAEE) and cardiorespiratory fitness with metabolic risk among individuals with recently diagnosed type 2 diabetes.Entities:
Mesh:
Year: 2013 PMID: 24196189 PMCID: PMC3857880 DOI: 10.1007/s00125-013-3069-8
Source DB: PubMed Journal: Diabetologia ISSN: 0012-186X Impact factor: 10.122
Anthropometric and metabolic characteristics of ADDITION-Plus participants (n = 394), stratified by sex
| Characteristic | Men ( | Women ( |
|
|---|---|---|---|
| Age, years | 60.2 (7.4) | 60.5 (7.4) | 0.71 |
| Occupational socioeconomic class, % | 0.01 | ||
| Managerial | 47.2 | 31.9 | |
| Intermediate | 22.0 | 30.6 | |
| Routine and manual | 30.8 | 37.5 | |
| Height, cm | 174.9 (7.2) | 161.4 (6.9) | <0.001 |
| Weight, kg | 96.9 (16.7) | 85.9 (17.7) | <0.001 |
| BMI, kg/m2 | 31.6 (5.1) | 32.9 (6.0) | 0.03 |
| Waist circumference, cm | 111.3 (12.5) | 105.0 (13.0) | <0.001 |
| Systolic blood pressure, mmHg | 132.0 (16.7) | 125.9 (17.0) | <0.001 |
| Triacylglycerol, mmol/la | 1.7 (1.2–2.3) | 1.6 (1.1–2.1) | 0.06 |
| Total cholesterol, mmol/l | 4.2 (0.9) | 4.4 (0.8) | 0.008 |
| HDL-cholesterol, mmol/l | 1.1 (0.3) | 1.3 (0.3) | <0.001 |
| HbA1c, % | 6.7 (1.0) | 6.6 (0.8) | 0.68 |
| HbA1c, mmol/mol | 49.7 | 48.6 | |
| On glucose-lowering medication, % | 49.6 | 54.9 | 0.31 |
| On antihypertensive medication, % | 72.4 | 70.1 | 0.63 |
| On lipid-lowering medication, % | 74.0 | 79.9 | 0.19 |
| Total energy intake, kJ/daya | 7,272 (6,130, 8,489) | 6,602 (5,711, 8,489) | 0.06 |
| Percentage of energy from fat, % | 30.6 (5.8) | 30.9 (5.7) | 0.62 |
| Alcohol intake, g/daya | 6.0 (1.0, 15.0) | 2.0 (0.0, 5.0) | <0.001 |
| PAEE, kJ kg-1 day-1 b | 37.6 (18.2) | 29.6 (13.5) | <0.001 |
| Average sleep duration, h/day | 8.1 (1.1) | 8.7 (0.9) | <0.001 |
| Duration SED-time, h/dayb,c | 9.1 (2.7) | 9.0 (2.4) | 0.69 |
| Duration SED-time, h/dayb,d | 10.3 (2.6) | 10.5 (2.2) | 0.50 |
| Duration MVPA, h/dayb,c | 1.4 (1.2) | 1.1 (0.9) | 0.007 |
| Duration MVPA, h/dayb,d | 0.88 (0.92) | 0.43 (0.48) | <0.001 |
|
| 33.4 (28.1, 37.4) | 25.2 (20.2, 31.9) | <0.001 |
Data are means (SD) unless stated otherwise
aMedian (IQR)
bIndividually calibrated where available (n = 291), otherwise group calibrated (n = 103)
c1 MET defined using individual estimate of RMR [21]
d1 MET defined using 71.2 J min−1 kg−1
e available for 291 participants (196 men and 95 women)
Crude and adjusted linear associations between SED-time and time spent in MVPA, PAEE and with subcomponents of metabolic risk and clustered metabolic risk in the ADDITION-Plus trial cohort (n = 394)
| Metabolic risk | SED-time (h/day), β (95% CI) | MVPA (h/day), β (95% CI) | PAEE (kJ kg−1 day−1), β (95% CI) |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Crude | Adjustedb | Adjustedb + MVPA | Crude | Adjustedb | Adjustedb + SED-time | Crude | Adjustedb | Crude | Adjustedb | |
| Waist, cm | 0.80 (0.31, 1.29)* | 0.97 (0.46, 1.48)* | 0.68 (0.01, 1.35)* | −1.09 (−2.24, 0.07) | −2.01 (−3.18, −0.85)* | −1.03 (−2.54, 0.49) | −0.16 (−0.24, −0.09)* | −0.27 (−0.35, −0.20)* | −0.39 (−0.54, −0.24)* | −0.62 (−0.78, −0.46)* |
| Systolic blood pressure, mmHg | 0.38 (−0.27, 1.03) | 0.07 (−0.62, 0.75) | −0.51 (−1.37, 0.36) | −1.86 (−3.36, −0.36)* | −1.36 (−2.89, 0.18) | −2.07 (−4.03, −0.11)* | −0.09 (−0.19, 0.01) | −0.07 (−0.18, 0.04) | −0.16 (−0.37, 0.05) | −0.23 (−0.48, 0.02) |
| HbA1c, % | 0.00 (−0.03, 0.04) | 0.02 (−0.02, 0.05) | 0.03 (−0.02, 0.07) | 0.01 (−0.07, 0.09) | 0.00 (−0.08, 0.08) | 0.04 (−0.07, 0.14) | 0.00 (−0.01, 0.01) | 0.00 (−0.01, 0.01) | 0.00 (−0.01, 0.01) | 0.00 (−0.02, 0.01) |
| Log | 0.01 (−0.01, 0.03) | 0.02 (−0.01, 0.04) | 0.03 (0.00, 0.06)* | 0.02 (−0.03, 0.07) | 0.01 (−0.04, 0.06) | 0.05 (−0.01, 0.11) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.01) | 0.00 (−0.01, 0.01) |
| HDL-cholesterol, mmol/l | 0.00 (−0.01, 0.01) | −0.01 (−0.02, 0.002) | −0.02 (−0.03, −0.001)* | −0.02 (−0.05, 0.01) | −0.002 (−0.03, 0.02) | −0.02 (−0.06, 0.01) | −0.001 (−0.003, 0.000) | 0.001 (−0.001, 0.002) | −0.006 (−0.010, −0.002)* | 0.00 (−0.01, 0.00) |
| zMS | 0.11 (0.01, 0.21)* | 0.16 (0.06, 0.26)* | 0.16 (0.03, 0.29)* | −0.07 (−0.30, 0.17) | −0.22 (−0.45, 0.00) | 0.01 (−0.28, 0.30) | −0.01 (−0.03, 0.00) | −0.03 (−0.05, −0.02)* | −0.02 (−0.05, 0.02) | −0.06 (−0.10, −0.03)* |
| zMSc | 0.28 (0.02, 0.54)* | 0.42 (0.16, 0.67)* | 0.42 (0.09, 0.75)* | −0.07 (−0.34, 0.19) | −0.25 (−0.50, 0.00) | 0.01 (−0.32, 0.33) | −0.21 (−0.47, 0.05) | −0.55 (−0.81, −0.28)* | −0.15 (−0.46, 0.16) | −0.58 (−0.89, −0.27)* |
Values for SED-time and MVPA use individualised RMR [21] as definition for 1 MET
a n = 291
bAll coefficients are adjusted for age, sex, intervention group, occupational socioeconomic class, smoking status, sleep duration, total energy intake, percentage of energy from fat, and alcohol intake. All outcomes except zMS and waist circumference are additionally adjusted for waist circumference. Systolic and diastolic blood pressure are additionally adjusted for the use of antihypertensive drugs (yes/no); HbA1c is additionally adjusted for the use of glucose-lowering drugs (yes/no); triacylglycerol is additionally adjusted for the use of lipid-lowering drugs (yes/no); HDL-cholesterol is additionally adjusted for the use of lipid-lowering drugs (yes/no); and zMS is additionally adjusted for the use of antihypertensive drugs (yes/no), glucose-lowering drugs (yes/no), and lipid-lowering drugs (yes/no). zMS is a continuously distributed variable for clustered metabolic risk calculated by summing standardised values for waist circumference, triacylglycerol, HbA1c, systolic blood pressure and the inverse of HDL-cholesterol
cDifference in zMS per SD difference in SED-time, MVPA, PAEE or
* p < 0.05
Fig. 1Associations of SED-time, MVPA, PAEE and cardiorespiratory fitness with clustered metabolic risk. Mean SED-time in the lower (reference), middle and higher tertile groups was 6.4 (range 1.2–8.0), 9.1 (range 8.0–10.4) and 11.6 (range 10.4–16.4) h/day, respectively (a). Mean time spent in MVPA in the lower, middle and higher tertile groups was 0.4 (range 0.0–0.6), 1.0 (range 0.6–1.5) and 2.4 (range 1.5–6.1) h/day, respectively (b). Mean PAEE in the lower, middle and higher tertile groups was 18.9 (range 5.6–24.7), 31.2 (range 24.8–39.4) and 50.3 (range 39.6–98.8) kJ kg−1 day−1, respectively (c). Mean cardiorespiratory fitness in the lower (reference), middle and higher tertile groups was 21.0 (range 11.3–26.9), 31.0 (range 27.1–34.6) and 38.7 (range 34.8–58.6) ml O2 kg−1 min−1, respectively (d). Data are the zMS for each group (95% CI), adjusted for age, sex, intervention group, occupational socioeconomic class, smoking status, sleep duration, total energy intake, percentage energy from fat, alcohol intake, and use of antihypertensive drugs, glucose-lowering drugs and lipid-lowering drugs. SED-time is additionally adjusted for MVPA, and MVPA is additionally adjusted for SED-time. p values for trend across categories for SED-time (a), MVPA (b), PAEE (c) and cardiorespiratory fitness (d) were p = 0.04, p = 0.72, p < 0.001 and p = 0.001, respectively